15 September 2021>: Clinical Research
Development and Validation of a Prevalence Model for Latent Autoimmune Diabetes in Adults (LADA) Among Patients First Diagnosed with Type 2 Diabetes Mellitus (T2DM)
Zhida Wang 1ABCDEF* , Jie Zhang 2ABCDEF* , Hui Xu 3CDEF , Liming Chen 1ADEFG* , Abigail Dove 4ADEFDOI: 10.12659/MSM.932725
Med Sci Monit 2021; 27:e932725
Table 2 Comparison of the clinical features between model development and validation groups.
Clinical features | Model development group (n=632) | Model validation group (n=298) | Z/t/χ2 | P value |
---|---|---|---|---|
Age | 57 (49, 61) | 56 (47, 62) | −0.366 | 0.714 |
Ketosis | 46 (7.3%) | 17 (5.7%) | 0.794 | 0.373 |
Abdominal type obesity | 534 (84.5%) | 249 (83.6%) | 0.133 | 0.715 |
Smoking | 336 (53.2%) | 142 (47.7%) | 2.464 | 0.116 |
Clinical testing | ||||
HbA1c (%) | 7.8 (7, 8.9) | 7.6 (6.8, 8.7) | − | 0.009 |
FPG | 8.43 (7.60, 9.68) | 8.42 (7.44, 9.54) | −0.748 | 0.454 |
1hPG | 17.07±2.57 | 16.71±2.73 | 1.966 | 0.050 |
2hPG | 16.95 (14.85, 19.37) | 17.25±3.64 | −0.398 | 0.691 |
1hINS | 47.48 (31.75, 71.39) | 47.97 (32.70, 75.33) | −0.397 | 0.691 |
2hINS | 55.70 (36.23, 88.94) | 60.84 (41.22, 93.35) | − | 0.049 |
FCP | 2.41 (1.90, 3.06) | 2.31 (1.85, 3.02) | −1.413 | 0.158 |
1hCP | 5.08 (3.99, 6.30) | 4.81 (3.78, 6.13) | − | 0.029 |
2hCP | 6.48 (5.21, 8.37) | 6.38 (5.13, 7.99) | −1.073 | 0.283 |
Pancreatic β-cell function | ||||
PG-AUC | 30.02 (26.83, 32.85) | 29.31 (26.31, 32.91) | −1.375 | 0.169 |
1hPG-AUC | 12.86 (11.63, 14.11) | 12.53 (11.31, 14.17) | − | 0.046 |
2hPG-AUC | 17.04 (15.19, 18.81) | 16.86 (14.86, 18.92) | −0.859 | 0.390 |
INS-AUC | 83.37 (56.62, 127.50) | 86.11 (60.65, 135.45) | −0.953 | 0.341 |
1hINS-AUC | 31.70 (21.18, 47.51) | 32.02 (21.49, 48.49) | −0.307 | 0.759 |
2hINS-AUC | 51.55 (34.81, 78.55) | 56.24 (38.05, 86.14) | −1.278 | 0.201 |
CP-AUC | 9.67 (7.74, 11.93) | 9.26 (7.45, 11.63) | −1.948 | 0.051 |
1hCP-AUC | 3.79 (3.06, 4.65) | 3.57 (2.81, 4.59) | − | 0.036 |
2hCP-AUC | 5.83 (4.65, 7.29) | 5.63 (4.51, 6.98) | −1.684 | 0.092 |
HOMA2-β (%) | 52.90 (41.23, 67.48) | 50.35 (40.05, 67.70) | −0.487 | 0.626 |